Annual FCF
-$588.34 M
-$230.74 M-64.53%
31 December 2023
Summary:
Sarepta Therapeutics annual free cash flow is currently -$588.34 million, with the most recent change of -$230.74 million (-64.53%) on 31 December 2023. During the last 3 years, it has fallen by -$613.60 million (-2428.76%). SRPT annual FCF is now -2428.76% below its all-time high of $25.26 million, reached on 31 December 2020.SRPT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$107.96 M
-$93.74 M-658.96%
30 September 2024
Summary:
Sarepta Therapeutics quarterly free cash flow is currently -$107.96 million, with the most recent change of -$93.74 million (-658.96%) on 30 September 2024. Over the past year, it has increased by +$47.52 million (+30.56%). SRPT quarterly FCF is now -117.45% below its all-time high of $618.67 million, reached on 31 March 2020.SRPT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$480.40 M
+$47.52 M+9.00%
30 September 2024
Summary:
Sarepta Therapeutics TTM free cash flow is currently -$480.40 million, with the most recent change of +$47.52 million (+9.00%) on 30 September 2024. Over the past year, it has increased by +$134.80 million (+21.91%). SRPT TTM FCF is now -281.23% below its all-time high of $265.07 million, reached on 31 March 2020.SRPT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -64.5% | +30.6% | +21.9% |
| 3 y3 years | -2428.8% | +19.2% | +26.5% |
| 5 y5 years | -30.8% | -40.5% | -1.1% |
SRPT Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -2428.8% | at low | -659.0% | +62.0% | -65.2% | +26.5% |
| 5 y | 5 years | -2428.8% | at low | -117.5% | +62.0% | -281.2% | +39.6% |
| alltime | all time | -2428.8% | at low | -117.5% | +62.0% | -281.2% | +39.6% |
Sarepta Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$107.96 M(+659.0%) | -$480.40 M(-9.0%) |
| June 2024 | - | -$14.22 M(-95.0%) | -$527.92 M(-19.3%) |
| Mar 2024 | - | -$284.52 M(+286.1%) | -$653.88 M(+11.1%) |
| Dec 2023 | -$588.34 M(+64.5%) | -$73.70 M(-52.6%) | -$588.34 M(-4.4%) |
| Sept 2023 | - | -$155.48 M(+10.9%) | -$615.20 M(+15.2%) |
| June 2023 | - | -$140.19 M(-36.0%) | -$534.14 M(+13.7%) |
| Mar 2023 | - | -$218.97 M(+117.8%) | -$469.85 M(+31.4%) |
| Dec 2022 | -$357.60 M(-26.1%) | -$100.56 M(+35.1%) | -$357.60 M(+22.9%) |
| Sept 2022 | - | -$74.42 M(-1.9%) | -$290.88 M(-16.9%) |
| June 2022 | - | -$75.89 M(-28.9%) | -$350.03 M(-10.1%) |
| Mar 2022 | - | -$106.73 M(+215.4%) | -$389.18 M(-19.6%) |
| Dec 2021 | -$483.97 M(-2015.7%) | -$33.84 M(-74.7%) | -$483.97 M(-25.9%) |
| Sept 2021 | - | -$133.57 M(+16.1%) | -$653.27 M(-16.6%) |
| June 2021 | - | -$115.04 M(-42.9%) | -$783.19 M(-1.5%) |
| Mar 2021 | - | -$201.52 M(-0.8%) | -$794.93 M(-3246.5%) |
| Dec 2020 | $25.26 M(-104.9%) | -$203.15 M(-22.9%) | $25.26 M(-46.7%) |
| Sept 2020 | - | -$263.49 M(+107.8%) | $47.36 M(-79.8%) |
| June 2020 | - | -$126.77 M(-120.5%) | $233.99 M(-11.7%) |
| Mar 2020 | - | $618.67 M(-441.7%) | $265.07 M(-151.4%) |
| Dec 2019 | -$516.09 M(+14.7%) | -$181.05 M(+135.6%) | -$516.09 M(+8.6%) |
| Sept 2019 | - | -$76.86 M(-19.7%) | -$475.03 M(-10.8%) |
| June 2019 | - | -$95.69 M(-41.1%) | -$532.66 M(-5.5%) |
| Mar 2019 | - | -$162.50 M(+16.1%) | -$563.81 M(+25.3%) |
| Dec 2018 | -$449.82 M(+77.6%) | -$139.99 M(+4.1%) | -$449.82 M(+30.2%) |
| Sept 2018 | - | -$134.49 M(+6.0%) | -$345.41 M(+24.9%) |
| June 2018 | - | -$126.83 M(+161.5%) | -$276.58 M(+16.2%) |
| Mar 2018 | - | -$48.51 M(+36.3%) | -$238.12 M(-6.0%) |
| Dec 2017 | -$253.21 M(+0.2%) | -$35.58 M(-45.8%) | -$253.21 M(-16.2%) |
| Sept 2017 | - | -$65.66 M(-25.7%) | -$302.21 M(+1.3%) |
| June 2017 | - | -$88.37 M(+39.0%) | -$298.33 M(+17.4%) |
| Mar 2017 | - | -$63.60 M(-24.8%) | -$254.02 M(+0.5%) |
| Dec 2016 | -$252.69 M(+63.8%) | -$84.58 M(+36.9%) | -$252.69 M(+25.8%) |
| Sept 2016 | - | -$61.78 M(+40.2%) | -$200.91 M(+7.5%) |
| June 2016 | - | -$44.06 M(-29.2%) | -$186.94 M(+8.5%) |
| Mar 2016 | - | -$62.27 M(+89.8%) | -$172.29 M(+11.7%) |
| Dec 2015 | -$154.30 M(-0.7%) | -$32.81 M(-31.4%) | -$154.30 M(+2.6%) |
| Sept 2015 | - | -$47.80 M(+62.5%) | -$150.40 M(-0.3%) |
| June 2015 | - | -$29.42 M(-33.6%) | -$150.81 M(-9.0%) |
| Mar 2015 | - | -$44.27 M(+53.1%) | -$165.75 M(+6.7%) |
| Dec 2014 | -$155.36 M(+126.9%) | -$28.91 M(-40.1%) | -$155.36 M(+7.1%) |
| Sept 2014 | - | -$48.22 M(+8.7%) | -$145.01 M(+22.5%) |
| June 2014 | - | -$44.35 M(+30.9%) | -$118.35 M(+36.2%) |
| Mar 2014 | - | -$33.88 M(+82.6%) | -$86.89 M(+26.9%) |
| Dec 2013 | -$68.47 M(+122.0%) | -$18.55 M(-13.9%) | -$68.47 M(+19.1%) |
| Sept 2013 | - | -$21.55 M(+67.1%) | -$57.50 M(+31.2%) |
| June 2013 | - | -$12.90 M(-16.6%) | -$43.83 M(+18.5%) |
| Mar 2013 | - | -$15.46 M(+104.0%) | -$36.99 M(+19.9%) |
| Dec 2012 | -$30.84 M(+18.7%) | -$7.58 M(-3.9%) | -$30.84 M(+3.9%) |
| Sept 2012 | - | -$7.89 M(+30.1%) | -$29.69 M(+0.1%) |
| June 2012 | - | -$6.06 M(-34.9%) | -$29.65 M(+19.1%) |
| Mar 2012 | - | -$9.31 M(+44.8%) | -$24.89 M(-4.2%) |
| Dec 2011 | -$25.98 M(+51.4%) | -$6.43 M(-18.0%) | -$25.98 M(+18.4%) |
| Sept 2011 | - | -$7.84 M(+500.1%) | -$21.95 M(+26.4%) |
| June 2011 | - | -$1.31 M(-87.4%) | -$17.36 M(-16.3%) |
| Mar 2011 | - | -$10.40 M(+334.7%) | -$20.75 M(+20.9%) |
| Dec 2010 | -$17.16 M | -$2.39 M(-26.6%) | -$17.16 M(+2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$3.26 M(-30.5%) | -$16.79 M(+7.6%) |
| June 2010 | - | -$4.69 M(-31.1%) | -$15.60 M(-0.6%) |
| Mar 2010 | - | -$6.82 M(+236.8%) | -$15.70 M(+45.4%) |
| Dec 2009 | -$10.79 M(-20.4%) | -$2.02 M(-2.1%) | -$10.79 M(-7.6%) |
| Sept 2009 | - | -$2.07 M(-56.8%) | -$11.68 M(-16.7%) |
| June 2009 | - | -$4.79 M(+150.7%) | -$14.02 M(+31.0%) |
| Mar 2009 | - | -$1.91 M(-34.3%) | -$10.70 M(-21.1%) |
| Dec 2008 | -$13.56 M(-49.4%) | -$2.91 M(-34.0%) | -$13.56 M(-25.9%) |
| Sept 2008 | - | -$4.41 M(+199.1%) | -$18.30 M(-4.5%) |
| June 2008 | - | -$1.47 M(-69.1%) | -$19.17 M(-24.7%) |
| Mar 2008 | - | -$4.76 M(-37.7%) | -$25.47 M(-5.0%) |
| Dec 2007 | -$26.80 M(+21.5%) | -$7.65 M(+45.0%) | -$26.80 M(+9.4%) |
| Sept 2007 | - | -$5.28 M(-32.1%) | -$24.50 M(-3.1%) |
| June 2007 | - | -$7.77 M(+27.3%) | -$25.29 M(+11.9%) |
| Mar 2007 | - | -$6.10 M(+14.2%) | -$22.59 M(+2.4%) |
| Dec 2006 | -$22.07 M(+36.8%) | -$5.35 M(-11.9%) | -$22.07 M(+0.0%) |
| Sept 2006 | - | -$6.07 M(+19.4%) | -$22.07 M(+28.7%) |
| June 2006 | - | -$5.08 M(-8.9%) | -$17.15 M(+0.5%) |
| Mar 2006 | - | -$5.58 M(+4.4%) | -$17.07 M(+5.8%) |
| Dec 2005 | -$16.14 M(-35.1%) | -$5.34 M(+364.7%) | -$16.14 M(+11.4%) |
| Sept 2005 | - | -$1.15 M(-77.0%) | -$14.48 M(-25.5%) |
| June 2005 | - | -$5.00 M(+7.5%) | -$19.43 M(-10.1%) |
| Mar 2005 | - | -$4.65 M(+26.0%) | -$21.62 M(-13.0%) |
| Dec 2004 | -$24.85 M(+30.0%) | -$3.69 M(-39.5%) | -$24.85 M(-4.8%) |
| Sept 2004 | - | -$6.10 M(-15.1%) | -$26.10 M(+10.3%) |
| June 2004 | - | -$7.19 M(-8.8%) | -$23.67 M(+19.1%) |
| Mar 2004 | - | -$7.88 M(+59.5%) | -$19.87 M(+3.9%) |
| Dec 2003 | -$19.12 M(-17.0%) | -$4.94 M(+34.6%) | -$19.12 M(+2.6%) |
| Sept 2003 | - | -$3.67 M(+8.4%) | -$18.63 M(-4.8%) |
| June 2003 | - | -$3.39 M(-52.5%) | -$19.56 M(-21.3%) |
| Mar 2003 | - | -$7.13 M(+60.2%) | -$24.84 M(+7.8%) |
| Dec 2002 | -$23.04 M(+35.5%) | -$4.45 M(-3.3%) | -$23.04 M(-4.3%) |
| Sept 2002 | - | -$4.60 M(-46.9%) | -$24.08 M(+3.7%) |
| June 2002 | - | -$8.67 M(+62.9%) | -$23.22 M(+25.4%) |
| Mar 2002 | - | -$5.32 M(-3.0%) | -$18.51 M(+8.9%) |
| Dec 2001 | -$17.00 M(+71.0%) | -$5.48 M(+46.7%) | -$17.00 M(+12.5%) |
| Sept 2001 | - | -$3.74 M(-5.8%) | -$15.11 M(+12.9%) |
| June 2001 | - | -$3.97 M(+4.2%) | -$13.38 M(+9.0%) |
| Mar 2001 | - | -$3.81 M(+5.9%) | -$12.28 M(+23.5%) |
| Dec 2000 | -$9.94 M(+27.5%) | -$3.60 M(+79.2%) | -$9.94 M(+19.1%) |
| Sept 2000 | - | -$2.01 M(-29.9%) | -$8.34 M(+1.3%) |
| June 2000 | - | -$2.86 M(+94.2%) | -$8.24 M(+8.7%) |
| Mar 2000 | - | -$1.47 M(-26.3%) | -$7.57 M(-2.9%) |
| Dec 1999 | -$7.80 M(-13.3%) | -$2.00 M(+5.3%) | -$7.80 M(-3.7%) |
| Sept 1999 | - | -$1.90 M(-13.6%) | -$8.10 M(-6.9%) |
| June 1999 | - | -$2.20 M(+29.4%) | -$8.70 M(-1.1%) |
| Mar 1999 | - | -$1.70 M(-26.1%) | -$8.80 M(-2.2%) |
| Dec 1998 | -$9.00 M(+172.7%) | -$2.30 M(-8.0%) | -$9.00 M(+12.5%) |
| Sept 1998 | - | -$2.50 M(+8.7%) | -$8.00 M(+23.1%) |
| June 1998 | - | -$2.30 M(+21.1%) | -$6.50 M(+38.3%) |
| Mar 1998 | - | -$1.90 M(+46.2%) | -$4.70 M(+42.4%) |
| Dec 1997 | -$3.30 M(+94.1%) | -$1.30 M(+30.0%) | -$3.30 M(+65.0%) |
| Sept 1997 | - | -$1.00 M(+100.0%) | -$2.00 M(+100.0%) |
| June 1997 | - | -$500.00 K(0.0%) | -$1.00 M(+100.0%) |
| Mar 1997 | - | -$500.00 K | -$500.00 K |
| Dec 1996 | -$1.70 M | - | - |
FAQ
- What is Sarepta Therapeutics annual free cash flow?
- What is the all time high annual FCF for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual FCF year-on-year change?
- What is Sarepta Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly FCF year-on-year change?
- What is Sarepta Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM FCF year-on-year change?
What is Sarepta Therapeutics annual free cash flow?
The current annual FCF of SRPT is -$588.34 M
What is the all time high annual FCF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual free cash flow is $25.26 M
What is Sarepta Therapeutics annual FCF year-on-year change?
Over the past year, SRPT annual free cash flow has changed by -$230.74 M (-64.53%)
What is Sarepta Therapeutics quarterly free cash flow?
The current quarterly FCF of SRPT is -$107.96 M
What is the all time high quarterly FCF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly free cash flow is $618.67 M
What is Sarepta Therapeutics quarterly FCF year-on-year change?
Over the past year, SRPT quarterly free cash flow has changed by +$47.52 M (+30.56%)
What is Sarepta Therapeutics TTM free cash flow?
The current TTM FCF of SRPT is -$480.40 M
What is the all time high TTM FCF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM free cash flow is $265.07 M
What is Sarepta Therapeutics TTM FCF year-on-year change?
Over the past year, SRPT TTM free cash flow has changed by +$134.80 M (+21.91%)